Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products. The Company’s initial product, the Proteograph product suite leverages its engineered nanoparticle (NP) technology to provide large-scale access to the proteome. The Proteograph product suite is an integrated solution that is comprised of consumables, an automation instrument, and software. Its approach is based on engineered NPs that enable unbiased sampling of intact proteins across the dynamic range of the proteome, capturing a myriad of molecular information at the level of protein variants as well as protein-protein interactions (PPIs). It is focused on adoption of the Proteograph with customers in the proteomics and genomics markets. The Company is initially focused on research applications for the Proteograph product Suite and are selling and marketing the Proteograph for research use only (RUO) eliminates the need for complex workflows required by other unbiased approaches.
During the most recent quarter, 8K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.